Tactile Medical Lands Exclusive U.S. Rights to ElastiMed's MyoSleeve for VA and DoD Patients
TCMD has more than doubled off its 52-week low of $9.415.
Summary
Tactile Medical announced an exclusive U.S. distribution agreement with ElastiMed for MyoSleeve, a wearable compression device for VA and DoD patients. The deal includes a $3 million upfront payment and minimum purchase commitments, expanding Tactile's portfolio into earlier-stage chronic swelling care.
Key Events · M&A and Partnerships · TCMD
-
Exclusive Distribution Agreement Signed
Tactile Medical entered into an exclusive U.S. distribution agreement with ElastiMed for MyoSleeve, a wearable non-pneumatic compression device for the lower leg, targeting VA and DoD patients.
-
Upfront Payment and Commitments
To support commercialization, Tactile made a $3 million upfront payment to ElastiMed and committed to minimum purchase obligations and marketing/sales promotion.
-
Product Expansion into Earlier-Stage Care
MyoSleeve expands Tactile's portfolio by providing a treatment option for patients in earlier stages of chronic swelling who may not yet require more intensive pneumatic compression therapy.
-
Leveraging Existing Infrastructure
Tactile plans to use its established sales organization, billing expertise, and patient support infrastructure to drive MyoSleeve adoption and market access.
Analysis · TCMD · Industrial Applications And Services
Tactile Medical has secured an exclusive U.S. distribution agreement with ElastiMed for MyoSleeve, a discreet, battery-powered wearable compression device for the lower leg, targeting VA and DoD patients. The partnership broadens Tactile's product line into earlier-stage chronic swelling treatment, complementing its existing pneumatic compression devices. Under the terms, Tactile paid $3 million upfront and committed to minimum purchase obligations and marketing support. By leveraging its established sales and reimbursement infrastructure, the company aims to drive commercialization of this new, FDA-cleared therapy, potentially opening a fresh revenue stream within the government healthcare market.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCMD was trading at $29.83 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $672.9M. The 52-week trading range was $9.42 to $37.77. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.